Explanation of why Novamex could take control of SRGE by
Explanation of why Novamex could take control of SRGE by buying 75% of its shares.
Quote:
Ask yourself this - all SRGE would need to do is default on their loans and MSJ could probably have grounds to take those assets back. Or perhaps commit some act of fraud - which I suspect the SEC suspension suggested just that. They had no choice but to pick up their dog and pony show and go elsewhere. Taking the mines back due to a default or fraud claim would tick many off - so why not pretend they were actually doing a "buyout" instead and take all of you along for the ride.
The first problem with this argument is the fact that monies due to Novamex is in a form of a promissory note, not a secured promissory note. If Novamex et al's plan were to position themselves to easily take the assets back, they would have signed a secured note. As long as the note is not secured by the assets of the company, Novamex cannot just take it back. MSJ cannot just take it back. There is no "taking it back."
The only way to "take the assets back" is to purchase them. In this case, Novamex being a shareholder and debt holder, the asset purchase has to be in consideration for assumption of debt and all shares of the corporation.
Whether you like it or not, this transaction is legal and will go through.
Southridge Enterprises Inc. (SRGE) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...
Continue Reading
Changing the Game with Lifestyle Medicine When it comes to healthcare, you're always going to have the skeptics grousing about the old ways. But what happens when you take an old idea and turbocharge it with modern tech? That's where the American College of Lifestyle Medicine (ACLM) and eClinicalWorks step in. They’re throwing a new wrench into the electronic health...
Continue Reading
The Storm Hits Stevanato: GLP-1 Blues Well, ain't this a fine pickle for Stevanato Group S.p.A. (NYSE:STVN). November 3, 2026, turned into quite the ride for those holding STVN shares. A tough third-quarter report dropped like a ton of bricks, driving the shares down after they coughed up a lower outlook for GLP-1 volumes in 2027. If you've been in the game long enough,...
Continue Reading
A New Chapter for an Old Favorite Dust off your digital pets, folks! Tamagotchi is not just a thing of the past. It's busting out of its shell to celebrate a big 3-0 with a splash—and get this—on Roblox. Who would've thought a plastic egg with pixels would still be out there thriving in the ether of childhood nostalgia three decades later? But it is, and it’s taking...
Continue Reading
A Grand Gathering of Robotics Minds Walking into KINTEX, Seoul's suburban behemoth of an exhibition center, you'll find a buzz that rivals the excitement of a stock floor on earnings day. It's ROBOTWORLD 2026, a stage set for tech titans and ambitious startups alike, all throwing in their chips on AI and robotics. From November 4th to 7th, 402 companies hailing from 17...
Continue Reading
The latest chapter in 3M’s legal saga reads like a courtroom drama, but this time, the company's shelling out big bucks to sidestep prolonged courtroom battles. They're committing to a $5.8 billion payout over several years, aiming to put a lid on a massive batch of PFAS-related lawsuits. It’s like they’re cleaning the spill with a velvet mop, but the trick is...
Continue Reading
Strategic Leadership for an Evolving Market Prepare your portfolios, folks. DarioHealth Corp. (NASDAQ:DRIO) is gearing up to ride a seismic shift in healthcare. John R. Palumbo's appointment as Chairman of the Board marks a bold move as Dario looks to dominate the new convergence of consumer-directed and payer-funded healthcare. This isn't just a change of guard; it's a...
Continue Reading
Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...
Continue Reading
Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...
Continue Reading
Compass's Legal Rumble: Shareholders Take Note You know there’s trouble when a firm’s every effort at glassy-eyed optimism is slapped with a lawsuit. We've seen this song and dance far too often, and now Compass, Inc. (NYSE: COMP) takes center stage. Schall, Brown & Schwartz LLP is rallying the troops for a knock-down-drag-out class action lawsuit, accusing Compass of...
Continue Reading
s of Cautious Optimism - Continue Reading"
aria-label="Continue reading: Farmer Sentiment Rises, Hints of Cautious Optimism">
Continue Reading